Dumont P, Atassi G, De Jager R
Clin Exp Metastasis. 1983 Oct-Dec;1(4):349-57. doi: 10.1007/BF00121197.
The effect of inicarone (L7035), a potent fibrinolytic, alone or in combination, was investigated on spontaneously metastasizing Lewis lung carcinoma (implanted intramuscularly) to verify whether it could prevent the formation of metastases. After intraperitoneal and oral administration, inicarone did not show any cytotoxicity since the survival of animals was not prolonged. Its activity was compared to that of warfarin, an anticoagulant: both drugs were inactive when administered in curative treatment and inicarone even enhanced the number of lung metastases. When administered in combination with cyclophosphamide, an antiproliferative agent, inicarone did not induce any synergism or antagonism, but this combination did not inhibit tumour growth or metastasis spreading. Moreover, when inicarone was combined with a potent antimetastatic agent, Nocodazole, it was shown to be in competition with the latter agent and totally overshadowed its activity; since inicarone had no antimetastatic effect, the number of metastases rose dramatically.
研究了强效纤溶剂イニカロン(L7035)单独或联合使用对自发转移的Lewis肺癌(肌肉内植入)的影响,以验证其是否能预防转移灶的形成。经腹腔和口服给药后,イニカロン未显示出任何细胞毒性,因为动物的生存期并未延长。将其活性与抗凝剂华法林的活性进行了比较:两种药物在进行治疗性给药时均无活性,且イニカロン甚至增加了肺转移灶的数量。当与抗增殖剂环磷酰胺联合使用时,イニカロン未产生任何协同或拮抗作用,但这种联合用药并未抑制肿瘤生长或转移扩散。此外,当イニカロン与强效抗转移剂诺考达唑联合使用时,发现它与后者存在竞争关系,并完全掩盖了后者的活性;由于イニカロン没有抗转移作用,转移灶的数量急剧增加。